← SynDRA
BUPARLISIB
SynDRA canonical compound SYN0029034 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | PIK3CA |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
- PIK3CA
- PIK3CG
- PIK3CB
- PIK3CD
- PIK3R1
- PIK3R2
- PIK3R3
- PIK3R5
Mechanisms of action (all sources)
- PI3K inhibitor
- PIK3R1 INHIBITOR
- PIK3CB INHIBITOR
- PIK3CG INHIBITOR
- PIK3CA INHIBITOR
- PIK3R2 INHIBITOR
- PIK3CD INHIBITOR
- PIK3R5 INHIBITOR
- PIK3R3 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MTOR
- PIK3R1
- PRKDC
- PIK3C3
- AKR1C3
- SYK
- PIK3C2B
- PGRMC1
- PI4KB
- PHKG2
- AAK1
- PIM1
- PEBP1
- PDXK
- PDGFRB
- PASK
- PARP1
- PAK4
- PAK2
- PFKP
- PIP4K2A
- OPA1
- PRKACG
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACB
- PIP4K2C
- PRKACA
- PRKAA1
- PLK4
- PKN2
- PKN1
- PKMYT1
- PAICS
- NUAK2
- OLA1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- IFNG
- KSYK
- MITF
- NSD2
- PIK3R5
- TFE3
- TP53
Cross-references
Synonyms
- BKM-120
- BKM-120NX
- BKM120-NX
- NVP-BKM-120
- NVP-BKM120
- BKM120
- 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
- NVP-BKM 120
- BKM 120
- Buparlisib (BKM120)
- BKM120 (NVP-BKM120, Buparlisib)
- 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
- BKM 120NX
- 5-[2,6-Di(Morpholin-4-Yl)pyrimidin-4-Yl]-4-(Trifluoromethyl)pyridin-2-Amine
- 0ZM2Z182GD
- CHEMBL2017974
- CHEBI:71954
- 944396-07-0 (free base)
- 5-[2,6-Di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine.
- Buparlisib [INN]
- Buparlisib [USAN:INN]
- UNII-0ZM2Z182GD
- 5-[2,6-Di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine
- SD5
- Buparlisib; BKM120
- 3sd5
- Buparlisib (USAN/INN)
- BUPARLISIB [USAN]
- BUPARLISIB [WHO-DD]
- MLS006010984
- SCHEMBL146956
- GTPL7878
- BKM120,NVP-BKM120
- BKM-120 (PI3K)
- DTXSID50241486
- EX-A189
- HMS3295I15
- HMS3655D16
Look up BUPARLISIB in the interactive SynDRA portal →